Contributions
Abstract: P811
Type: Poster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Introduction: Fampridine blocks the voltage-dependent K channels increasing the velocity of conduction in nerves. It is a drug approved for the treatment of walking difficulties in patients with multiple sclerosis (MS).
Material and methods: Observational, prospective study of patients with MS on treatment with fampridine. Timed 25 Foot Walk (T25FW), MS Walking Scale-12 (MSWS-12) and Symbol Digit Modalities Test (SDMT) were done before and 14 days after treatment start. Patients with a good response to fampridine (reduction of at least 20% in T25FW and 6 points in MSWS-12) were also evaluated at 3 and 6 months.
Results: 68 patients were included. The tase of responders was 55.9% at 14 days, 33.8% at month 3 and 29.4% at month 6. A significant improvement (p< 0.001) in SDMT was obtained at day 14, month 3 and 6 (5.49%, 13.62% y 2.83%). The changes in SDMT were not related with age, EDSS or the basal results of this test. Differences in SDMT were independent of changes in T25FW (0.168, p=0.226) and MSWS-12 (0.212, p=0.128).
Conclusions: An improvement in the velocity of mental processing was detected in patients on treatment with fampridine. These results were independent of the effect on walking scales. It is possible that several patients get a benefit of treatment with fampridine even when they do not achieve the actual criteria for response.
Disclosure:
- Puente Hernández M: nothing to disclosure.
- Lagorio AN: nothing to disclosure.
- Costa Arpín E: has served as speaker or consultant for Biogen Idec, Merck Serono, Bayer Health Care, Genzyme, TEVA and UCB Pharma.
- Prieto González JM. has served as advisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. He also has received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.
Abstract: P811
Type: Poster
Abstract Category: Therapy - symptomatic - 33 Treatment of specific symptoms
Introduction: Fampridine blocks the voltage-dependent K channels increasing the velocity of conduction in nerves. It is a drug approved for the treatment of walking difficulties in patients with multiple sclerosis (MS).
Material and methods: Observational, prospective study of patients with MS on treatment with fampridine. Timed 25 Foot Walk (T25FW), MS Walking Scale-12 (MSWS-12) and Symbol Digit Modalities Test (SDMT) were done before and 14 days after treatment start. Patients with a good response to fampridine (reduction of at least 20% in T25FW and 6 points in MSWS-12) were also evaluated at 3 and 6 months.
Results: 68 patients were included. The tase of responders was 55.9% at 14 days, 33.8% at month 3 and 29.4% at month 6. A significant improvement (p< 0.001) in SDMT was obtained at day 14, month 3 and 6 (5.49%, 13.62% y 2.83%). The changes in SDMT were not related with age, EDSS or the basal results of this test. Differences in SDMT were independent of changes in T25FW (0.168, p=0.226) and MSWS-12 (0.212, p=0.128).
Conclusions: An improvement in the velocity of mental processing was detected in patients on treatment with fampridine. These results were independent of the effect on walking scales. It is possible that several patients get a benefit of treatment with fampridine even when they do not achieve the actual criteria for response.
Disclosure:
- Puente Hernández M: nothing to disclosure.
- Lagorio AN: nothing to disclosure.
- Costa Arpín E: has served as speaker or consultant for Biogen Idec, Merck Serono, Bayer Health Care, Genzyme, TEVA and UCB Pharma.
- Prieto González JM. has served as advisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. He also has received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.